BR112012018843A8 - radioimunoconjugado que se liga a cd37 humano, composição farmacêutica, uso do radioimunoconjugado, método para tratamento de uma malignidade de célula b e kit para a produção do radioimunoconjugado - Google Patents
radioimunoconjugado que se liga a cd37 humano, composição farmacêutica, uso do radioimunoconjugado, método para tratamento de uma malignidade de célula b e kit para a produção do radioimunoconjugadoInfo
- Publication number
- BR112012018843A8 BR112012018843A8 BR112012018843A BR112012018843A BR112012018843A8 BR 112012018843 A8 BR112012018843 A8 BR 112012018843A8 BR 112012018843 A BR112012018843 A BR 112012018843A BR 112012018843 A BR112012018843 A BR 112012018843A BR 112012018843 A8 BR112012018843 A8 BR 112012018843A8
- Authority
- BR
- Brazil
- Prior art keywords
- radioimmunoconjugate
- kit
- binding
- treating
- producing
- Prior art date
Links
- 229940051022 radioimmunoconjugate Drugs 0.000 title 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000003719 b-lymphocyte Anatomy 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000036210 malignancy Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29952410P | 2010-01-29 | 2010-01-29 | |
NO20100143 | 2010-01-29 | ||
NO20100143A NO331080B1 (no) | 2010-01-29 | 2010-01-29 | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
US61/299,524 | 2010-01-29 | ||
PCT/EP2011/051231 WO2011092295A2 (en) | 2010-01-29 | 2011-01-28 | Novel radioimmunoconjugates and uses thereof |
Publications (4)
Publication Number | Publication Date |
---|---|
BR112012018843A2 BR112012018843A2 (pt) | 2017-10-17 |
BR112012018843A8 true BR112012018843A8 (pt) | 2017-12-19 |
BR112012018843B1 BR112012018843B1 (pt) | 2020-09-24 |
BR112012018843B8 BR112012018843B8 (pt) | 2020-12-22 |
Family
ID=44319900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012018843A BR112012018843B8 (pt) | 2010-01-29 | 2011-01-28 | radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado |
Country Status (26)
Country | Link |
---|---|
US (2) | US8628749B2 (pt) |
EP (2) | EP2528627B1 (pt) |
JP (2) | JP5646652B2 (pt) |
KR (2) | KR101893720B1 (pt) |
CN (2) | CN102762230B (pt) |
AU (1) | AU2011209441B2 (pt) |
BR (1) | BR112012018843B8 (pt) |
CA (1) | CA2786655C (pt) |
DK (2) | DK2528627T3 (pt) |
ES (2) | ES2469140T3 (pt) |
HK (2) | HK1179157A1 (pt) |
HR (1) | HRP20140538T1 (pt) |
IL (2) | IL221091A (pt) |
MX (2) | MX2012008695A (pt) |
NO (1) | NO331080B1 (pt) |
NZ (1) | NZ601055A (pt) |
PH (1) | PH12017501038B1 (pt) |
PL (1) | PL2528627T3 (pt) |
PT (1) | PT2528627E (pt) |
RS (1) | RS53346B (pt) |
RU (2) | RU2560587C9 (pt) |
SG (1) | SG182685A1 (pt) |
SI (1) | SI2528627T1 (pt) |
UA (1) | UA108631C2 (pt) |
WO (1) | WO2011092295A2 (pt) |
ZA (1) | ZA201205007B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015501654A (ja) * | 2011-12-13 | 2015-01-19 | ノルディック ナノベクター アーエス | 治療用キメラ型抗cd37抗体hh1 |
RU2014140119A (ru) * | 2012-03-30 | 2016-05-27 | Иммьюноджен, Инк. | Способы повышения эффективности терапии на основе cd37 |
CN103933575B (zh) * | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
AU2014276827B2 (en) * | 2013-06-07 | 2018-11-15 | Nordic Nanovector Asa | Method for upregulating antigen expression |
TWI646108B (zh) | 2013-08-01 | 2019-01-01 | 艾澤西公司 | 結合至cd37蛋白質之抗體藥物結合物(adc) |
JP6869187B2 (ja) * | 2015-04-07 | 2021-05-12 | メモリアル スローン ケタリング キャンサー センター | ナノ粒子イムノコンジュゲート |
GB201600328D0 (en) * | 2016-01-08 | 2016-02-24 | Univ Oslo Hf | Anti-CD37 chimeric antigen receptors and immune cells expressing them |
MX2019003029A (es) * | 2016-09-16 | 2019-09-13 | Nordic Nanovector Asa | Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano. |
KR102406510B1 (ko) | 2017-07-03 | 2022-06-10 | 현대자동차주식회사 | 연료전지 시스템용 수소 공급 방법 |
CN109550061A (zh) * | 2017-09-26 | 2019-04-02 | 南京江原安迪科正电子研究发展有限公司 | 一种用于放射性核素标记抗体的试剂盒及应用 |
EP3713607A1 (en) * | 2017-11-22 | 2020-09-30 | Nordic Nanovector ASA | Radioimmunoconjugates in combination with other drugs as treatment against nhl |
WO2023057583A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 |
WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
CN114081969A (zh) * | 2021-11-23 | 2022-02-25 | 成都纽瑞特医疗科技股份有限公司 | 标记的小分子抗体、及其标记方法和应用 |
CN117285631A (zh) * | 2023-11-24 | 2023-12-26 | 原子高科股份有限公司 | 用于放射性免疫治疗的Lu-177标记MUC1抗体 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
CN1437478A (zh) * | 2000-04-25 | 2003-08-20 | Idec药物公司 | 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗 |
RU2005122033A (ru) * | 2002-12-13 | 2006-01-27 | Митра Медикал Текнолоджи Аб (Se) | Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом |
US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
JP4874090B2 (ja) * | 2003-01-31 | 2012-02-08 | イミューノメディクス、インコーポレイテッド | 治療薬および診断薬を投与するための方法および組成物 |
WO2005084179A2 (en) * | 2003-12-01 | 2005-09-15 | Immunomedics, Inc. | Improved method for preparing conjugates of proteins and chelating agents |
WO2007014278A2 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | B-cell reduction using cd37-specific and cd20-specific binding molecules |
PE20090499A1 (es) * | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
-
2010
- 2010-01-29 NO NO20100143A patent/NO331080B1/no not_active IP Right Cessation
-
2011
- 2011-01-28 DK DK11700972.0T patent/DK2528627T3/da active
- 2011-01-28 NZ NZ601055A patent/NZ601055A/en not_active IP Right Cessation
- 2011-01-28 CA CA2786655A patent/CA2786655C/en active Active
- 2011-01-28 ES ES11700972.0T patent/ES2469140T3/es active Active
- 2011-01-28 US US13/522,678 patent/US8628749B2/en active Active
- 2011-01-28 ES ES13195682.3T patent/ES2592402T3/es active Active
- 2011-01-28 CN CN201180007272.9A patent/CN102762230B/zh not_active Expired - Fee Related
- 2011-01-28 JP JP2012550464A patent/JP5646652B2/ja active Active
- 2011-01-28 PT PT117009720T patent/PT2528627E/pt unknown
- 2011-01-28 CN CN201410353070.5A patent/CN104338154B/zh active Active
- 2011-01-28 KR KR1020177018914A patent/KR101893720B1/ko active IP Right Grant
- 2011-01-28 SG SG2012054607A patent/SG182685A1/en unknown
- 2011-01-28 RS RS20140300A patent/RS53346B/en unknown
- 2011-01-28 DK DK13195682.3T patent/DK2705857T3/en active
- 2011-01-28 BR BR112012018843A patent/BR112012018843B8/pt not_active IP Right Cessation
- 2011-01-28 PL PL11700972T patent/PL2528627T3/pl unknown
- 2011-01-28 RU RU2012135430/10A patent/RU2560587C9/ru active
- 2011-01-28 UA UAA201208485A patent/UA108631C2/ru unknown
- 2011-01-28 EP EP11700972.0A patent/EP2528627B1/en active Active
- 2011-01-28 EP EP13195682.3A patent/EP2705857B1/en active Active
- 2011-01-28 WO PCT/EP2011/051231 patent/WO2011092295A2/en active Application Filing
- 2011-01-28 SI SI201130157T patent/SI2528627T1/sl unknown
- 2011-01-28 KR KR1020127020917A patent/KR101758409B1/ko active IP Right Grant
- 2011-01-28 MX MX2012008695A patent/MX2012008695A/es active IP Right Grant
- 2011-01-28 MX MX2015000391A patent/MX342539B/es unknown
- 2011-01-28 RU RU2015127407A patent/RU2664475C1/ru active
- 2011-01-28 AU AU2011209441A patent/AU2011209441B2/en not_active Ceased
-
2012
- 2012-07-04 ZA ZA2012/05007A patent/ZA201205007B/en unknown
- 2012-07-24 IL IL221091A patent/IL221091A/en active IP Right Grant
-
2013
- 2013-05-23 HK HK13106111.6A patent/HK1179157A1/xx not_active IP Right Cessation
- 2013-12-09 US US14/100,756 patent/US9358309B2/en active Active
-
2014
- 2014-06-09 HR HRP20140538AT patent/HRP20140538T1/hr unknown
- 2014-09-11 HK HK14109175.2A patent/HK1195736A1/zh not_active IP Right Cessation
- 2014-11-05 JP JP2014225005A patent/JP5855209B2/ja active Active
-
2015
- 2015-03-02 IL IL237507A patent/IL237507A0/en active IP Right Grant
-
2017
- 2017-06-05 PH PH12017501038A patent/PH12017501038B1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012018843A8 (pt) | radioimunoconjugado que se liga a cd37 humano, composição farmacêutica, uso do radioimunoconjugado, método para tratamento de uma malignidade de célula b e kit para a produção do radioimunoconjugado | |
BR112015010595A2 (pt) | composição cosmética, processo para alisar fibras de queratina e uso de uma composição | |
BR112014010460A2 (pt) | composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica | |
BRPI1010775A2 (pt) | composição, método para preparar uma composição, e, uso de uma composição. | |
BR112013009142A2 (pt) | "composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa" | |
BR112014011096A2 (pt) | composição cosmética, processo cosmético para o revestimento de matérias queratínicas e kit | |
BR112015012123A8 (pt) | composições para a recuperação de uma microbiota fecal e métodos para produzir e usar as mesmas. | |
BR112013014599A2 (pt) | composição imunogênica, uso de uma composição imunogênica, processo para preparar uma composição imunogênica, método para a fabricação de uma composição imunogênca estável, e, kit | |
BR112014016288A8 (pt) | ferramenta de rotação vertebral direta e método de uso da mesma | |
BR112014010391A2 (pt) | composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica | |
BR112013022927A2 (pt) | composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição | |
BR112014028755A2 (pt) | composição de argamassa de poliuretano, processo para preparação da composição de argamassa de poliuretano, e, uso de uma composição de argamassa de poliuretano. | |
BR112014026815A2 (pt) | composição cosmética, processo cosmético e uso de uma composição cosmética | |
BRPI1010937A2 (pt) | composto, uso de um composto, e, método para tratar câncer | |
BR112013013127A2 (pt) | processo para a preparação de derivados de morfolinil antraciclina | |
BR112014015519A2 (pt) | composição para a tintura das fibras queratínicas e método para tingir as fibras queratínicas | |
BR112013030318A2 (pt) | composição, processo para o tratamento cosmético não terapêutico das matérias queratínicas e uso de uma composição. | |
BRPI0921399A2 (pt) | composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante | |
BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
BR112014031412A2 (pt) | método de preparação de uma composição, composição e seu uso, e kit. | |
BR112014015042A8 (pt) | composição farmacêutica, e, método para obter uma composição radiofarmacêutica | |
SG11201400462YA (en) | Inner phase thickened water-in-oil cosmetic composition | |
BR112014014242A2 (pt) | método de fortalecimento de fibras de cabelo e uso de uma composição para cabelo | |
BR112014026795A2 (pt) | composição cosmética , processo cosmético para tratar a matéria queratínica e uso de uma composição cosmética. | |
BR112012027145A2 (pt) | emulsão, composição de uso final e método para tratar uma condição cutânea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B65X | Notification of requirement for priority examination of patent application | ||
B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2594 DE 24/09/2020 QUANTO AO TITULO. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2759 DE 21-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |